SLN124 + Placebo
Phase 1/2Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polycythemia Vera
Conditions
Polycythemia Vera
Trial Timeline
Jan 26, 2023 → Mar 1, 2030
NCT ID
NCT05499013About SLN124 + Placebo
SLN124 + Placebo is a phase 1/2 stage product being developed by Silence Therapeutics for Polycythemia Vera. The current trial status is active. This product is registered under clinical trial identifier NCT05499013. Target conditions include Polycythemia Vera.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05499013 | Phase 1/2 | Active |
| NCT04718844 | Phase 1 | Completed |
| NCT04559971 | Phase 1 | Completed |
Competing Products
20 competing products in Polycythemia Vera
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sapablursen + Placebo | Ono Pharmaceutical | Phase 3 | 77 |
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| Bomedemstat | Merck | Phase 2 | 52 |
| Ruxolitinib + Hydroxycarbamide + Interferon-Alpha | Novartis | Phase 3 | 77 |
| ruxolitinib tablets | Novartis | Phase 3 | 77 |
| Ruxolitinib | Novartis | Pre-clinical | 23 |
| Ruxolitinib | Novartis | Phase 3 | 77 |
| Ruxolitinib + BAT | Novartis | Phase 2 | 52 |
| Hydroxyurea | Novartis | Approved | 85 |
| Best Available Therapy + Ruxolitinib | Novartis | Phase 3 | 77 |
| Smac Mimetic LCL161 | Novartis | Phase 2 | 52 |
| PEGASYS + Aspirin | Roche | Phase 2 | 52 |
| RG7388 + Pegasys | Roche | Phase 1 | 33 |
| Idasanutlin | Roche | Phase 2 | 52 |
| PEGASYS + Hydroxyurea + Aspirin | Roche | Phase 3 | 77 |
| Ropeginterferon alfa-2b | PharmaEssentia | Phase 2 | 51 |
| Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen | PharmaEssentia | Phase 3 | 76 |
| Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT) | PharmaEssentia | Phase 3 | 76 |
| Ropeginterferon alfa-2b | PharmaEssentia | Approved | 84 |
| P1101 + Low-dose aspirin | PharmaEssentia | Phase 2 | 51 |
Other Products from Silence Therapeutics
SLN360 + PlaceboPhase 2
44
Atu027 & gemcitabine in lead in safety period + Atu027 & gemcitabine in treatment arm 1 + Atu027 & gemcitabine in treatment arm 2Phase 1/2
33
Atu027Phase 1
25
SLN124 + PlaceboPhase 1
25
SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as PlaceboPhase 1
25